Nearly 1.8 million chickens in Colorado will be sent to slaughter due to the latest outbreak of bird flu. Meanwhile, ...
CureVac's share price has plummeted over 90% in the past five years due to vaccine efficacy issues and legal disputes. Learn ...
The US government has signed a $176 million deal with Moderna to develop an mRNA-based pandemic influenza vaccine, as reports ...
As fears of a pandemic mount, the biotech company’s mRNA vaccine trial is set to release Phase 1/2 results later this year, ...
InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here.
CureVac NV, a German biopharma company with its U.S. headquarters in Boston, is restructuring after signing a licensing deal ...
GSK reached a licensing agreement with mRNA-vaccine developer CureVac worth up to $1.8 billion to develop its vaccines for ...
Merck Mercuriadis to step down from Hipgnosis, infrastructure improvement delays impact UK’s renewable energy transition, ...
The U.S. government will pay the vaccine maker Moderna $176 million to accelerate development of a pandemic influenza vaccine ...
The U.S. government has awarded $176-million to Moderna MRNA-Q to advance development of its bird flu vaccine, the company said on Tuesday, as concerns rise over a multi-state outbreak of H5N1 ...
The US Department of Health and Human Services announced Tuesday a contract with Moderna to develop an mRNA vaccine that ...
The US government will pay Moderna $176 million to develop an mRNA vaccine against a pandemic influenza—an award given as the ...